Data availability This study involves the analysis of de-identified Electronic Health Record (EHR) data via the nference Federated Clinical Analytics Platform
How I chose top providers
Disclaimer These statements have not been evaluated by the FDA, and MIC+B12 injections are not approved to diagnose, treat, cure, or prevent any disease
The remaining authors declare no conflicts of interests
Sarwar Alam Chaudhary Registered Pharmacist, BHMS Scholar Reviewed Official Prescribing Label Warning Tirzepatide (Mounjaro / Zepbound) can cut oral birth control absorption by ~60% The manufacturers own label recommends switching to a non-oral contraceptive, or adding a barrier method, for 4 weeks after starting tirzepatide and after every dose increase
Retatrutide remains effective at preventing regain while the body stabilizes at reduced weight